Cite
HARVARD Citation
Nghiem, P. et al. (2021). Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. Journal for immunotherapy of cancer. 9 (4), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Nghiem, P. et al. (2021). Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. Journal for immunotherapy of cancer. 9 (4), p. . [Online].